Alvin Shih

Alvin Shih is a distinguished professional in the biopharmaceutical industry, currently serving as the CEO at Catamaran Bio, a company specializing in allogeneic CAR-NK cell therapies for diseases with significant unmet needs.

With a remarkable track record, Alvin has previously held CEO positions at Disarm Therapeutics, which was acquired by Eli Lilly & Co., and Enzyvant Therapeutics, acquired by Dainippon Sumitomo.

His expertise spans company creation and drug development across various phases, from early discovery to clinical and post-marketing stages, with a specific focus on Oncology, Rare Diseases, Neuroscience, and Immunology.

Alvin Shih's educational background includes an M.D. from the University of Alabama School of Medicine, an M.B.A. from Northwestern University's Kellogg School of Management, and a B.A. from Vanderbilt University.

Throughout his career, Alvin has held key roles such as President and CEO at Catamaran Bio, EVP and Head of R&D at Retrophin, Chief Operating Officer of Rare Disease Research at Pfizer, and Senior Engagement Manager at L.E.K. Consulting, LLC.

He has also contributed his expertise as a Resident Physician at Massachusetts General Hospital and a Business Analyst at McKinsey & Company.

Alvin Shih has extensive experience in therapeutic modalities including cell/tissue therapies, protein/RNA therapeutics, and small molecules, showcasing his versatility and innovation in the field of biopharmaceuticals.